DA Davidson assumed coverage of Phreesia (PHR) with a Buy rating and $33 price target The firm believes Phreesia has the ability to address a broader scope of problems on behalf of providers, patients, and pharma companies, which it argues should translate to durable double-digit growth and ongoing margin expansion.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia price target raised to $34 from $33 at Piper Sandler
- Phreesia price target raised to $38 from $34 at Canaccord
- Phreesia’s Strategic Growth and Financial Strength Justify Buy Rating Amidst AccessOne Acquisition
- Phreesia’s Strong Financial Performance and Strategic Acquisitions Justify Buy Rating
- Phreesia Reports First Net Income Positive Quarter